⚙️ Technology

COVID

1 story First seen Jul 19, 2026 Latest Jul 19, 2026

🧬 AI profile — grown from 6ic coverage Fluvoxamine is an antidepressant medication, primarily used to treat obsessive-compulsive disorder (OCD) and anxiety disorders. Recent studies suggest that it may also hold promise in treating long COVID symptoms, particularly reducing fatigue in patients. This breakthrough has sparked hope for potential new treatments for long COVID, a condition affecting millions worldwide.

Coverage by desk

Science 1

Coverage · last 14 days

Jul 7Jul 20

Recurring themes

long COVID ×1 fluvoxamine ×1 McMaster University ×1 Brazil ×1 clinical trial ×1

🕸 Connection map 🌌 Full galaxy →

Connected entities

Metformin ×1 University of British Columbia ×1 SARS-CoV-2 ×1 Fluvoxamine ×1 Brazilian ×1 Stanford University ×1 REVIVE-TOGETHER ×1 McMaster University ×1 Brazil ×1

Every story (1)

Breakthrough in Long COVID Treatment: Fluvoxamine Shows Promise in Reducing Fatigue

Science · Jul 19, 2026 · BlockchainSpace AI